Recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|21|3|300-306

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.21, Iss.3, 2015-05, pp. : 300-306

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Response to Gringeri et al.: ‘recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling’

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : e489-e492

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 766-771

John Wiley & Sons Inc

Access to resources Recommend Favorite

Half‐life extended factor VIII for the treatment of hemophilia A

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. S1, 2015-06 ,pp. : S176-S179

John Wiley & Sons Inc

Access to resources Recommend Favorite

Transition considerations for extended half‐life factor products

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 285-288

John Wiley & Sons Inc

Access to resources Recommend Favorite

Identification of aggregates in therapeutic formulations of recombinant full‐length factor VIII products by sedimentation velocity analytical ultracentrifugation

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 16, Iss. 2, 2018-02 ,pp. : 303-315

John Wiley & Sons Inc

Access to resources Recommend Favorite